CD8-reduced T cells for MDS/AML transformation of MPN

Current understanding

CD8-depleted/reduced donor T-cell products (Johns Hopkins) are being developed as a cellular therapy targeting MDS/AML arising from MPN progression — a setting that overlaps with the AP/BP MPN pre-transplant population. The approach aims to retain graft-versus-leukemia activity (via CD4 and other effectors) while limiting GVHD risk, positioning it as either a peri-transplant adjunct or a salvage option for transformed disease. FDA-grant-stage with no clinical outcomes reported.

Evidence log

• Foundation — FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases: cross-connection with post-transplant-relapse-ciml-nk: Both are cell-therapy approaches for high-risk MPN-transformation/post-transplant relapse settings (CD8-reduced T cells vs CIML NK cells), representing parallel cellular-immunotherapy bets on the same hard-to-treat population. (novelty: 3)

Open questions

Related